Answers are grounded in this paper and cite their sources.
Nivolumab monotherapy was better tolerated than nivolumab + ipilimumab; the tolerability of the combination was influenced by ipilimumab dose. These safety and exploratory findings merit further investigation of immunotherapies in glioblastoma.
No takes yet. Share an insight, caveat, or question.
Omuro et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: